Overview
SUSTAIN-6 (NEJM 2016, PMID 27633186) cardiovascular safety in T2D + high CV risk: 26% MACE reduction. Led to Ozempic's FDA approval.
PubMed citations
Related clinical pages
- STEP trial results
- SELECT trial results
- FLOW trial results
- Mechanism of action
- Dosing & pharmacology
- Contraindications
- Side effects
Key facts, checked November 20, 2026
SUSTAIN-6 (NEJM 2016) enrolled 3,297 adults with type 2 diabetes at high cardiovascular risk. The primary outcome of cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.6% on semaglutide and 8.9% on placebo (hazard ratio 0.74). Nonfatal stroke was less common (1.6% versus 2.7%), but diabetic retinopathy complications were more common with semaglutide, and the Ozempic injection label includes a warning about diabetic retinopathy complications. SUSTAIN-6 tested Ozempic for type 2 diabetes, not weight management.